- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03546322
Customized Registry Tool for Tracking Adherence to Clinical Guidelines for Head and Neck Cancers
Study Overview
Detailed Description
The investigators aim to implement and evaluate a health information technology (HIT) registry at an urban, public delivery system. The investigators will not assign specific interventions to the study participants, but rather observationally assess the effect of the HIT registry, designed to support routine medical care, on participants.
The investigators will use systems engineering methodologies to design, develop, and implement the platform. The platform will be implemented in the Otolaryngology - Head and Neck Surgery clinic that cares for patients with head and neck cancers. The study will assess patient outcomes and evaluate the time it takes for patients to progress through key treatment and post-treatment milestones before and after the HIT tool is implemented. The investigators will use models controlling for secular trend to estimate the effect of the tool on improving timely and successful completion of guideline-based care processes.
The HIT platform seeks to improve the monitoring and alerting functionality of existing systems. Specifically, it replaces paper-based systems previously used by the clinic to monitor its head and neck cancer patients. It will be implemented clinic-wide for all patients being treated for head and neck cancers. The investigators are not assigning a specific intervention to patients, but rather supporting the clinic and health system in the development of a population management platform that improves routine care processes. The platform is approved for clinical use and research by the San Francisco Health Network and the University of California, San Francisco.
The HIT platform users are clinicians who are responsible for monitoring patients with head and neck cancer and agree to partner with the investigators to improve monitoring processes. The clinicians involved may be asked to voluntarily participate in surveys, interviews, focus groups, and program evaluations. Patient medical records will be reviewed, but patients monitored on the registry will not be contacted by researchers.
Procedures are in place to monitor the registry. First, quality assurance is performed by the research team, information technology analysts, and software engineers. This includes checking that data in the platform matches source data, such as data entered in the electronic health record. In addition, the platform users are audited on a weekly basis. A data dictionary defining variables used in the platform exists and is updated as needed. Patients will be added to the registry by a clinician if they are diagnosed with head and neck cancer. The research team will support the clinicians in data analysis, although this will be performed with population-level, de-identified data. However, if unmediated adverse events are identified by the research team, the research team will alert the clinicians immediately. The HIT platform is designed to supplement, but not replace, the existing electronic health record. Data on the registry will be validated with source data and users will still engage with the source data and electronic health record as appropriate clinically and operationally.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- Zuckerberg San Francisco General Hospital and Trauma Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with head and neck surgery monitored by the Otolaryngology - Head and Neck Surgery Clinic
Exclusion Criteria:
- N/A
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Registry
Head and neck cancer patients monitored on registry
|
Patients who are diagnosed with head and neck cancer and monitored by the Otolaryngology - Head and Neck Surgery clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group.
The intervention is the implementation of a registry, designed to replace existing paper-based systems for tracking patients.
All head and neck cancer patients monitored by the clinic will be included.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Workup and Treatment Planning - Primary Outcome
Time Frame: From date of diagnosis to first date of treatment, assessed up to 5 years
|
Time from diagnosis to initiation of treatment
|
From date of diagnosis to first date of treatment, assessed up to 5 years
|
Treatment - Primary Outcome
Time Frame: 5 years
|
Proportion of patients that complete tumor board treatment recommendations
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Workup and Treatment Planning - Secondary Outcome #1
Time Frame: From date of diagnosis to presentation at tumor board, assessed up to 5 years
|
Time from diagnosis to presentation at tumor board
|
From date of diagnosis to presentation at tumor board, assessed up to 5 years
|
Workup and Treatment Planning - Secondary Outcome #2
Time Frame: From date of diagnosis to date of dental evaluation for patients undergoing radiation treatment, assessed up to 5 years
|
Time from diagnosis to dental evaluation
|
From date of diagnosis to date of dental evaluation for patients undergoing radiation treatment, assessed up to 5 years
|
Workup and Treatment Planning - Secondary Outcome #3
Time Frame: From date of diagnosis to date of first visit with oncology clinic, assessed up to 5 years
|
Time from diagnosis to first visit in oncology clinics
|
From date of diagnosis to date of first visit with oncology clinic, assessed up to 5 years
|
Treatment - Secondary Outcome
Time Frame: 6 weeks
|
Proportion of patients who complete post-treatment radiation
|
6 weeks
|
Loss to follow-up
Time Frame: 5 years
|
Proportion of patients who are lost to follow-up
|
5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Urmimala Sarkar, MD, MPH, University of California, San Francisco
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P30HS023558-1
- P30HS023558 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Neoplasms
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
AZ Sint-Jan AVRecruiting
-
IntraGel TherapeuticsNot yet recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHead and Neck CarcinomaUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Completed
-
Jonsson Comprehensive Cancer CenterWithdrawnHead and Neck CarcinomaUnited States
Clinical Trials on Registry
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...RecruitingAchondroplasia | HypochondroplasiaItaly
-
Emory UniversityRecruiting
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Recruiting
-
University of UlmRecruiting
-
Swiss Hemophilia NetworkRecruiting
-
University of California, San FranciscoAgency for Healthcare Research and Quality (AHRQ)TerminatedProstatic NeoplasmsUnited States
-
Clinica Universidad de Navarra, Universidad de...Recruiting
-
Newcastle-upon-Tyne Hospitals NHS TrustRecruitingBethlem Myopathy | Ullrich Congenital Muscular Dystrophy 1, Digenic, Col6A1/Col6A2 | Ullrich Congenital Muscular Dystrophy 1, Autosomal Recessive | Ullrich Congenital Muscular Dystrophy 1, Autosomal Dominant | Bethlem Myopathy 1, Autosomal Recessive | UCMD | BTHLM1United Kingdom
-
Newcastle UniversityLudwig-Maximilians - University of Munich; LGMD2i Research Fund; CureLGMD2iRecruitingLimb Girdle Muscular Dystrophy | Congenital Muscular Dystrophy | LGMDR9 | LGMD2I | Walker-Warburg Syndrome | Muscle-Eye-Brain Disease | FKRP Gene MutationUnited Kingdom
-
Main Line HealthPinnacle Biologics Inc.Recruiting